Study supports additional COVID-19 vaccine doses for immunocompromised
In a study of over 89,000 adults hospitalized with COVID-19 symptoms, prior vaccination with two doses of the Pfizer or Moderna vaccine was 77% effective in preventing COVID-19 in immunocompromised patients compared with 90% effective in immunocompetent patients, the Centers for Disease Control and Prevention reported today. The authors recommend three doses and a booster for immunocompromised individuals receiving mRNA COVID-19 vaccines, consistent with CDC recommendations.
Related News Articles
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…